An assessment of six placebo-managed medical trials with one,134 whole individuals concluded that cannabinoids (nabiximols, dronabinol, and THC/CBD) had been related to a greater normal improvement on the Ashworth scale for spasticity in multiple sclerosis patients in contrast with placebo, although this didn't access statistical significance. Some individuals with PTSD https://what-is-herbal-ecstacy57890.diowebhost.com/91584768/the-cannabis-world-vienna-diaries